Resolvins Lipid Mediators: Potential Therapeutic Targets in Alzheimer and Parkinson Disease

Neuroscience. 2022 Dec 15:507:139-148. doi: 10.1016/j.neuroscience.2022.11.001. Epub 2022 Nov 11.

Abstract

Inflammation and resolution are highly programmed processes involving a plethora of immune cells. Lipid mediators synthesized from arachidonic acid metabolism play a pivotal role in orchestrating the signaling cascades in the game of inflammation. The majority of the studies carried out so far on inflammation were aimed at inhibiting the generation of inflammatory molecules, whereas recent research has shifted more towards understanding the resolution of inflammation. Owing to chronic inflammation as evident in neuropathophysiology, the resolution of inflammation together with the class of lipid mediators actively involved in its regulation has attracted the attention of the scientific community as therapeutic targets. Both omega-three polyunsaturated fatty acids, eicosapentaenoic acid and docosahexaenoic acid, orchestrate a vital regulatory role in inflammation development. Resolvins derived from these fatty acids comprise the D-and E-series resolvins. A growing body of evidence using in vitro and in vivo models has revealed the pro-resolving and anti-inflammatory potential of resolvins. This systematic review sheds light on the synthesis, specialized receptors, and resolution of inflammation mediated by resolvins in Alzheimer's and Parkinson's disease.

Keywords: Alzheimer’s disease; Parkinson’s disease; arachidonic acid; lipid mediators; resolvins.

Publication types

  • Systematic Review
  • Review

MeSH terms

  • Alzheimer Disease* / drug therapy
  • Docosahexaenoic Acids / metabolism
  • Eicosapentaenoic Acid / metabolism
  • Humans
  • Inflammation / metabolism
  • Inflammation Mediators
  • Parkinson Disease* / drug therapy

Substances

  • Eicosapentaenoic Acid
  • Docosahexaenoic Acids
  • Inflammation Mediators